Astria Therapeutics, Inc. Financial Ratios
ATXS / Health Care|FY2024 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2024 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2024)
Return on Equity
-29.5%
Profit Margin
-
Net Income / Revenue
Asset Turnover
-
Revenue / Total Assets
Equity Multiplier
1.07
Total Assets / Equity
Profitability
Gross Margin
-
Operating Margin
-
EBITDA
-$94.3M
EBITDA Margin
-
Liquidity
Current Ratio
17.49
Quick Ratio
17.49
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
-
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2024 · SEC 10-K · Updated Feb 28, 2026
Earnings Quality
Accrual Ratio
-4.4%
-2.6pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.